Table 2 Characteristics of study participants (i.e., analytic sample) versus noncompleters (i.e., those who did not complete the baseline survey and/or testing) (N = 1,084).

From: Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer

Characteristic

Group

Analytic sample (n = 803)

Noncompletersa (n = 281)

pb

Sex

Female

258 (75%)

84 (25%)

0.49

 

Male

545 (73%)

197 (27%)

 

Race

White

678 (77%)

200 (23%)

<0.001

 

Black/African American

54 (50%)

55 (50%)

 
 

Asian

28 (74%)

10 (26%)

 
 

American Indian/Alaska Native

1 (100%)

0 (0%)

 
 

Other

35 (76%)

11 (24%)

 
 

Missing

7 (58%)

5 (42%)

 

Ethnicity

Hispanic

23 (74%)

8 (26%)

0.92

 

Not Hispanic

737 (73%)

268 (27%)

 
 

Unknown/missing

43 (90%)

5 (10%)

 

Cancer type

Ovarian

142 (89%)

18 (11%)

<0.001

 

Prostate

390 (77%)

117 (23%)

 
 

Pancreas

271 (65%)

146 (35%)

 

Type of result

PV

84 (79%)

23 (22%)

0.05

 

NV

607 (77%)

177 (23%)

 
 

VUS

112 (69%)

51 (31%)

 
 

Missing

0 (0%)

30 (100%)

 

Site

Memorial Sloan Kettering

376 (93%)

30 (7%)

<0.001

 

University of Pennsylvania

427 (63%)

251 (37%)

 

Age

Years, mean (SD)

67.1 (9.9)

70.2 (10.4)

<0.001

  1. NV no variant, PV pathogenic variant, VUS variant of uncertain significance.
  2. aThe majority of study noncompleters (89.3%) completed genetic testing but not the baseline survey (see Fig. 1 for details).
  3. bp values are based on a series of Chi-square tests, except for age, which is tested using an independent-samples t-test.
Back to article page